About this episode
Another day, another b cell podcast. Seems to be all the rage! This week I discuss the recently published NEJM trial of the anti CD20 agent obinutuzumab in lupus nephritis. Worth a read and listen, paper can be found here: https://www.nejm.org/doi/full/10.1056/NEJMoa2410965
Get every episode summarized
Each time The Evidence Based Rheumatology Podcast publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from The Evidence Based Rheumatology Podcast
E133: Obinutuzumab for SLE (ALLEGORY)
The Evidence Based Rheumatology Podcast
E132: Romosozumab vs teriparatide for osteoproosis (STRUCTURE)
The Evidence Based Rheumatology Podcast
E131: A Sham-Controlled Sham of a Trial: RESET-RA
The Evidence Based Rheumatology Podcast
E130: Telitacicept for SLE
The Evidence Based Rheumatology Podcast